Skip to main content
SpringerLink
Log in

Pelvic Lymphadenectomy for Prostate and Bladder Cancer

  • Chapter
  • First Online:
Pelvic Cancer Surgery

  • 1955 Accesses

Abstract

Pelvic lymph node dissection (PLND) is an integral part of radical urologic surgery for pelvic malignancies. For many years PLND was part and parcel of radical retropubic prostatectomy for prostate cancer, though recent guidelines recommend performing PLND in conjunction with radical prostatectomy only when the nomogram-predicted risk of lymph nodes being involved with metastatic prostate cancer is greater than 2–2.5 %. This is not only because there is significant potential morbidity to PLND, but also because the therapeutic benefit of dissections in such cases is quite limited. A standard PLND is nevertheless recommended for all intermediate-risk men, and an extended PLND is recommended for high-risk men.

The greatest predictor of lymph node involvement may well be the percentage of cores that are found positive on initial prostate biopsy (number of positive cores/total number of cores taken). It is recommended that one of several nomograms be used to define this risk in individual cases before deciding on whether or not to perform PLND and to what extent. While the therapeutic benefit of PLND is controversial, it is clear that men with small volume nodal disease (typically, one or two positive nodes) can be cured by removing these nodes alone and without adjuvant therapy. Strong consideration should be given to androgen deprivation therapy for most men found to have positive nodes however, particularly with several positive nodes, or lymph node density of 15 % or greater.

PLND as part of a radical cystectomy for bladder cancer remains a nonnegotiable part of this operation. It appears that there is no patient who should not receive PLND during radical cystectomy, as positive lymph node rates are high in essentially all published series. An extended template PLND, superiorly to the uretero-iliac junction, is recommended for all radical cystectomy patients. High lymph node yields and a low positive lymph node density (<15–20 %) have both been associated with survival advantages, but of course extended templates do engender more morbidity than standard prostate cancer PLND templates. Morbidities associated with PLND include venous thromboembolic events, lymphocele, lower extremity edema, obturator nerve injury, and major vascular injury.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol. 1996;156(6):1969–71.

    Article  CAS  PubMed  Google Scholar 

  2. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491–9.

    Article  PubMed  Google Scholar 

  3. Heesakkers RA, Jager GJ, Hovels AM, de Hoop B, van den Bosch HC, Raat F, et al. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology. 2009;251(2):408–14.

    Article  PubMed  Google Scholar 

  4. National Comprehensive Cancer Network. Prostate Cancer (Version 2.2013). http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed August 1, 2013.

  5. Weight CJ, Reuther AM, Gunn PW, Zippe CR, Dhar NB, Klein EA. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Urology. 2008;71(1):141–5.

    Article  PubMed  Google Scholar 

  6. Berglund RK, Sadetsky N, DuChane J, Carroll PR, Klein EA. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol. 2007;177(2):526–9; discussion 529–30.

    Article  PubMed  Google Scholar 

  7. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170(5):1798–803.

    Article  PubMed  Google Scholar 

  8. Bluestein DL, Bostwick DG, Bergstralh EJ, Oesterling JE. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol. 1994;151(5):1315–20.

    CAS  PubMed  Google Scholar 

  9. Briganti A, Karakiewicz PI, Chun FK, Gallina A, Salonia A, Zanni G, et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol. 2007;51(6):1573–81.

    Article  PubMed  Google Scholar 

  10. Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61(3):480–7.

    Article  PubMed  Google Scholar 

  11. Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, Epstein JI, Walsh PC, Trock BJ, Partin AW. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111(1):22–9.

    Article  PubMed  Google Scholar 

  12. Yu JB, Makarov DV, Sharma R, Peschel RE, Partin AW, Gross CP. Validation of the partin nomogram for prostate cancer in a national sample. J Urol. 2010;183(1):105–11.

    Article  PubMed  Google Scholar 

  13. Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer. 2002;95(5): 1016–21.

    Article  PubMed  Google Scholar 

  14. Briganti A, Chun FK, Salonia A, Gallina A, Zanni G, Scattoni V, et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology. 2007;69(1):147–51.

    Article  PubMed  Google Scholar 

  15. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.

    Article  PubMed  Google Scholar 

  16. Cellini N, Luzi S, Mantini G, Mattiucci GC, Morganti AG, Digesu C, et al. Lymphatic drainage and CTV in carcinoma of the prostate. Rays. 2003;28(3):337–41.

    PubMed  Google Scholar 

  17. Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol. 2008;53(1):118–25.

    Article  PubMed  Google Scholar 

  18. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol. 2002;168(2):514–8; discussion 8.

    Article  PubMed  Google Scholar 

  19. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol. 2007;177(3):916–20.

    Article  PubMed  Google Scholar 

  20. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004;172(5 Pt 1):1840–4.

    Article  PubMed  Google Scholar 

  21. Touijer K, Rabbani F, Otero JR, Secin FP, Eastham JA, Scardino PT, et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1 %. J Urol. 2007;178(1):120–4.

    Article  PubMed  Google Scholar 

  22. Masterson TA, Bianco Jr FJ, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol. 2006;175(4):1320–4; discussion 1324–5.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002;167(4):1681–6.

    Article  PubMed  Google Scholar 

  24. Bochner BH, Herr HW, Reuter VE. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol. 2001;166(6):2295–6.

    Article  CAS  PubMed  Google Scholar 

  25. Stein JP, Penson DF, Cai J, Miranda G, Skinner EC, Dunn MA, et al. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol. 2007;177(3):876–81; discussion 881–2.

    Article  PubMed  Google Scholar 

  26. Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009;55(2):261–70.

    Article  PubMed  Google Scholar 

  27. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004;172(6 Pt 1):2252–5.

    Article  PubMed  Google Scholar 

  28. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol. 2004;172(5 Pt 1):1860–4.

    Article  PubMed  Google Scholar 

  29. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–9.

    Article  CAS  PubMed  Google Scholar 

  30. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, et al. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol. 2006;24(18):2735–42.

    Article  PubMed  Google Scholar 

  31. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ. Blute ML The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005;173(4):1121–5.

    Article  PubMed  Google Scholar 

  32. Murphy AM, Berkman DS, Desai M, Benson MC, McKiernan JM, Badani KK. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy. BJU Int. 2010;105(2):176–9.

    Article  PubMed  Google Scholar 

  33. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.

    CAS  PubMed  Google Scholar 

  34. Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 1998;160(6 Pt 1):2015–9; discussion 2020.

    CAS  PubMed  Google Scholar 

  35. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol. 2003;170(1):35–41.

    Article  PubMed  Google Scholar 

  36. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167(3):1295–8.

    Article  PubMed  Google Scholar 

  37. Tarin TV, Power NE, Ehdaie B, Sfakianos JP, Silberstein JL, Savage CJ, Sjoberg D, Dalbagni G, Bochner BH. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol. 2012;61(5):1025–30.

    Article  PubMed Central  PubMed  Google Scholar 

  38. May M, Herrmann E, Bolenz C, Tiemann A, Brookman-May S, Fritsche HM, Burger M, Buchner A, Gratzke C, Wülfing C, Trojan L, Ellinger J, Tilki D, Gilfrich C, Höfner T, Roigas J, Zacharias M, Gunia S, Wieland WF, Hohenfellner M, Michel MS, Haferkamp A, Müller SC, Stief CG, Bastian PJ. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol. 2011;59(5):712–8.

    Article  PubMed  Google Scholar 

  39. May M, Herrmann E, Bolenz C, Brookman-May S, Tiemann A, Moritz R, Fritsche HM, Burger M, Trojan L, Michel MS, Wülfing C, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Bastian PJ. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol. 2011;18(7):2018–25.

    Article  PubMed  Google Scholar 

  40. Leissner J, Hohenfellner R, Thüroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 2000;85(7):817–23.

    Article  CAS  PubMed  Google Scholar 

  41. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9.

    Article  PubMed  Google Scholar 

  42. Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol. 2004;172(4 Pt 1):1286–90.

    Article  PubMed  Google Scholar 

  43. Parkash V, Bifulco C, Feinn R, Concato J, Jain D. To count and how to count, that is the question: interobserver and intraobserver variability among pathologists in lymph node counting. Am J Clin Pathol. 2010;134(1):42–9.

    Article  PubMed  Google Scholar 

  44. Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 2006;107(10):2368–74.

    Article  PubMed  Google Scholar 

  45. Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol. 2008;179(3):873–8. doi:10.1016/j.jur0.2007.10.076; discussion 878, Epub 2008 Jan 25.

    Article  PubMed  Google Scholar 

  46. Roth B, Wissmeyer MP, Zehnder P, Birkhäuser FD, Thalmann GN, Krause TM, Studer UE. A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol. 2010;57(2):205–11.

    Article  PubMed  Google Scholar 

  47. Leissner J, Ghoneim MA, Abol-Enein H, Thüroff JW, Franzaring L, Fisch M, Schulze H, Managadze G, Allhoff EP, el-Baz MA, Kastendieck H, Buhtz P, Kropf S, Hohenfellner R, Wolf HK. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139–44.

    Article  CAS  PubMed  Google Scholar 

  48. Miocinovic R, Gong MC, Ghoneim IA, Fergany AF, Hansel DE, Stephenson AJ. Presacral and retroperitoneal lymph node involvement in urothelial bladder cancer: results of a prospective mapping study. J Urol. 2011;186(4):1269–73.

    Article  PubMed  Google Scholar 

  49. Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol. 2007;178(4 Pt 1):1218–23; discussion 1223–4.

    Article  PubMed  Google Scholar 

  50. Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, Miranda G, Birkhäuser F, Stein J, Burkhard FC, Daneshmand S, Thalmann GN, Gill IS, Skinner DG. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011;186(4):1261–8.

    Article  PubMed  Google Scholar 

  51. Capitanio U, Suardi N, Shariat SF, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009;103(10):1359–62. doi:10.1111/j.1464–410X.2008.08212.x. Epub 2008 Dec 8.

    Article  PubMed  Google Scholar 

  52. Brössner C, Pycha A, Toth A, Mian C, Kuber W. Does extended lymphadenectomy increase the morbidity of radical cystectomy? BJU Int. 2004;93(1):64–6.

    Article  PubMed  Google Scholar 

  53. Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol. 1982;128(1):34–6.

    CAS  PubMed  Google Scholar 

  54. Ball MW, Gorin MA, Allaf ME. Reducing morbidity of pelvic and retroperitoneal lymphadenectomy. Curr Urol Rep. 2013;14:488–95.

    Article  PubMed  Google Scholar 

  55. Musch M, Klevecka V, Roggenbuck U, Kroepfl D. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. J Urol. 2008;179(3):923–8; discussion 928–9.

    Article  PubMed  Google Scholar 

  56. Clark T, Parekh DJ, Cookson MS, Chang SS, Smith Jr ER, Wells N, Smith Jr J. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol. 2003;169(1):145–7; discussion 147–8.

    Article  PubMed  Google Scholar 

  57. Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, Roscigno M, Zanni G, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50(5):1006–13. Epub 2006 Aug 31.

    Article  PubMed  Google Scholar 

  58. Catalona WJ, Kadmon D, Crane DB. Effect of mini-dose heparin on lymphocele formation following extraperitoneal pelvic lymphadenectomy. J Urol. 1980;123(6):890–2.

    CAS  PubMed  Google Scholar 

  59. Gotto GT, Yunis LH, Guillonneau B, Touijer K, Eastham JA, Scardino PT, Rabbani F. Predictors of symptomatic lymphocele after radical prostatectomy and bilateral pelvic lymph node dissection. Int J Urol. 2011;18:291–6.

    Article  PubMed  Google Scholar 

  60. Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, Graefen M, Guazzoni G, Shariat SF, Stolzenburg JU, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Wilson TG. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):431–52.

    Article  PubMed  Google Scholar 

  61. Forrest JB, Clemens JQ, Finamore P, Leveillee R, Lippert M, Pisters L, Touijer K, Whitmore K, American Urological Association. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol. 2009;181(3):1170–7.

    Article  PubMed  Google Scholar 

  62. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):381S–453.

    Article  CAS  PubMed  Google Scholar 

  63. Eifler JB, Levinson AW, Hyndman ME, Trock BJ, Pavlovich CP. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy. J Urol. 2011;185(5):1661–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Christian P. Pavlovich MD, Michael A. Gorin MD, Philip M. Pierorazio MD & Jeffrey K. Mullins MD

Authors
  1. Christian P. Pavlovich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael A. Gorin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip M. Pierorazio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey K. Mullins MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian P. Pavlovich MD .

Editor information

Editors and Affiliations

  1. Urology, University Hospital of North Norway, Tromsø, Norway

    Hitendra R.H. Patel

  2. University College London Hospital, London, United Kingdom

    Tim Mould

  3. Laparoscopic and Robotic Surgery, University of Rochester Medical Center, Rochester, New York, USA

    Jean V. Joseph

  4. Colorectal Surgery, University Hospitals Case Medical Center, Cleveland, Ohio, USA

    Conor P. Delaney

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Pavlovich, C.P., Gorin, M.A., Pierorazio, P.M., Mullins, J.K. (2015). Pelvic Lymphadenectomy for Prostate and Bladder Cancer. In: Patel, H., Mould, T., Joseph, J., Delaney, C. (eds) Pelvic Cancer Surgery. Springer, London. https://doi.org/10.1007/978-1-4471-4258-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4258-4_8

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4257-7

  • Online ISBN: 978-1-4471-4258-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation